Commitments and Contingencies (Details) - USD ($) |
1 Months Ended | 3 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|---|
Jan. 19, 2021 |
Dec. 28, 2020 |
Apr. 30, 2021 |
Mar. 31, 2021 |
Mar. 31, 2020 |
Dec. 31, 2020 |
|
| Other Commitments [Line Items] | ||||||
| Audit committee findings | The primary investigative findings were: (i) the DABRA catheter frequently failed to calibrate and occasionally overheated, posing a risk of injury to physicians and patients; (ii) the Company’s explanations regarding its fourth quarter 2018 and first quarter 2019 sales created a risk of confusion because they did not explicitly reference inconsistent DABRA catheter performance and catheter failures; (iii) the Company failed to timely make at least two Medical Device Reports, or MDRs, to the FDA; (iv) the Company, out of a concern for the DABRA catheters’ performance, engaged in systematic efforts to replace product held by customers, which constituted product recalls, but were not documented as such, (v) the Company lack documentation of sufficient detail and specificity to support certain payments to physicians, ostensibly for training and consulting services, and as to three physicians did not accurately reflect the purpose and nature of approximately $300,000 of payments, which could be perceived as an improper attempt to obtain business or to gain special advantage, (vi) while the indication for use in the 510(k) clearance the Company obtained for the DABRA system is not for atherectomy, the Company’s salespeople were instructed to characterize DABRA as performing atherectomy and to encourage doctors to seek reimbursement using atherectomy codes, (vii) the Company’s determinations to direct potentially valuable benefits and opportunities to doctors were informed in part by sales prospects, and (viii) the Company received complaints regarding regulatory or compliance concerns that, because they implicated executive officers, should have been brought to the attention of the Board or the Audit Committee, but were not. | |||||
| Payments to physicians that lack documentation of sufficient detail | $ 300,000 | |||||
| Revenue | $ 1,118,000 | $ 1,374,000 | ||||
| Settlement Agreement [Member] | ||||||
| Other Commitments [Line Items] | ||||||
| Allegations description | (a) paid illegal remuneration to certain physicians to induce them to use the DABRA laser system in violation of the federal anti-kickback statute and (b) marketed the DABRA laser system for off-label use in atherectomy procedures despite product performance issues causing calibration and overheating problems, which posed a risk to physicians and patients (the “Covered Conduct”). | |||||
| Litigation settlement amount | $ 2,500,000 | |||||
| Payment for legal settlement | 2,400,000 | |||||
| Settlement amount , year 2021 | $ 500,000 | |||||
| Settlement year one | 2021 | |||||
| Settlement amount , year 2022 | $ 750,000 | |||||
| Settlement year two | 2022 | |||||
| Settlement amount , year 2023 | $ 1,000,000 | |||||
| Settlement year three | 2023 | |||||
| Settlement amount , year 2024 | $ 1,250,000 | |||||
| Settlement year four | 2024 | |||||
| Business acquisition, settlement amount | $ 5,000,000 | |||||
| Business acquisition additional settlement percentage | 4.00% | |||||
| Business acquisition, transaction costs | $ 100,000,000 | |||||
| Business acquisition change In control payments | 28,000,000 | |||||
| Settlement claim | 56,000,000 | |||||
| Settlement expense | 200,000 | |||||
| Loss contingency, payments | $ 2,700,000 | |||||
| Settlement accrued expenses | $ 100,000 | |||||
| Settlement Agreement [Member] | Subsequent Event [Member] | ||||||
| Other Commitments [Line Items] | ||||||
| Payment for legal settlement | $ 100,000 | |||||
| Settlement Agreement [Member] | Maximum [Member] | ||||||
| Other Commitments [Line Items] | ||||||
| Litigation settlement amount | $ 265,000 | |||||
| Revenue | $ 10,000,000 | |||||
| Integrity Agreement [Member] | ||||||
| Other Commitments [Line Items] | ||||||
| Agreement term | 5 years | |||||